Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome?

[1]  V. Yardley,et al.  American tegumentary leishmaniasis: Is antimonial treatment outcome related to parasite drug susceptibility? , 2006, The Journal of infectious diseases.

[2]  M. Ouellette,et al.  Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. , 2006, The Journal of infectious diseases.

[3]  S. K. Choudhuri,et al.  Sodium Antimony Gluconate Induces Generation of Reactive Oxygen Species and Nitric Oxide via Phosphoinositide 3-Kinase and Mitogen-Activated Protein Kinase Activation in Leishmania donovani-Infected Macrophages , 2006, Antimicrobial Agents and Chemotherapy.

[4]  A. Fairlamb,et al.  Drug Resistance in Leishmaniasis , 2006, Clinical Microbiology Reviews.

[5]  V. Yardley,et al.  The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. , 2005, The American journal of tropical medicine and hygiene.

[6]  S. Sundar,et al.  Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models , 2005, Parasitology Research.

[7]  A. Ranjan,et al.  Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar. , 2005, National Medical Journal of India.

[8]  A. Fairlamb,et al.  Dual Action of Antimonial Drugs on Thiol Redox Metabolism in the Human Pathogen Leishmania donovani* , 2004, Journal of Biological Chemistry.

[9]  S. Rijal,et al.  Antigen genes for molecular epidemiology of leishmaniasis: polymorphism of cysteine proteinase B and surface metalloprotease glycoprotein 63 in the Leishmania donovani complex. , 2004, The Journal of infectious diseases.

[10]  W. M. Elamin,et al.  Antimony-resistant Leishmania donovaniin eastern Sudan: incidence and in vitro correlation. , 2003, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit.

[11]  F. Chappuis,et al.  Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. , 2003, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[12]  S. Sundar,et al.  The In Vivo Susceptibility of Leishmania donovani to Sodium Stibogluconate Is Drug Specific and Can Be Reversed by Inhibiting Glutathione Biosynthesis , 2003, Antimicrobial Agents and Chemotherapy.

[13]  P. Das,et al.  Antileishmanial drugs cause up-regulation of interferon-gamma receptor 1, not only in the monocytes of visceral leishmaniasis cases but also in cultured THP1 cells , 2003, Annals of tropical medicine and parasitology.

[14]  A. Koçyiğit,et al.  Antimonial Therapy Induces Circulating Proinflammatory Cytokines in Patients with Cutaneous Leishmaniasis , 2002, Infection and Immunity.

[15]  S. Sundar.  Drug resistance in Indian visceral leishmaniasis , 2001, Tropical medicine & international health : TM & IH.

[16]  D. Zilberstein,et al.  Novel Intracellular SbV Reducing Activity Correlates with Antimony Susceptibility in Leishmania donovani * , 2001, The Journal of Biological Chemistry.

[17]  H. Murray,et al.  Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis. , 2000, The Journal of infectious diseases.

[18]  S. Sundar,et al.  Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  A. Périanin,et al.  Sodium Stibogluconate (Pentostam) Potentiates Oxidant Production in Murine Visceral Leishmaniasis and in Human Blood , 2000, Antimicrobial Agents and Chemotherapy.

[20]  H. Murray,et al.  Roles of Endogenous Gamma Interferon and Macrophage Microbicidal Mechanisms in Host Response to Chemotherapy in Experimental Visceral Leishmaniasis , 2000, Infection and Immunity.

[21]  S. Sundar,et al.  Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. , 1999, The Journal of infectious diseases.

[22]  R. Schreiber,et al.  Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis. , 1989, The Journal of clinical investigation.